PMID- 36320650
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230918
IS  - 2398-8835 (Electronic)
IS  - 2398-8835 (Linking)
VI  - 5
IP  - 6
DP  - 2022 Nov
TI  - Facial palsy as a manifestation of COVID-19: A systematic review of cases.
PG  - e887
LID - 10.1002/hsr2.887 [doi]
LID - e887
AB  - BACKGROUND AND AIMS: Facial palsy is a rare complication of the COVID-19 
      infection. Herein, we conducted a systematic review of all published cases of 
      facial palsy post-COVID-19 infection in an attempt to educate the general 
      population and medical practitioners regarding the likely occurrence of facial 
      palsy in COVID-19 patients, its detection, effective treatment plan, and 
      prognosis of the condition. METHODS: We searched PubMed, Google Scholar, and 
      Directory of Open Access Journals (DOAJ) from December 1, 2019 to September 21, 
      2021. RESULTS: We included 49 studies bearing accounts of 75 cases who had facial 
      palsy. The mean age of patients was 42.9 +/- 19.59 years, with a male-to-female 
      ratio of 8:7. The majority of the cases were reported from Brazil (n = 14), USA 
      (n = 9), Turkey (n = 9), and Spain (n = 9). Noticeably, 30.14% of COVID-19 
      patients were diagnosed with Guillain-Barre syndrome. In total, 22.97% of 
      patients complained of bilateral facial paralysis (n = 17), whereas ipsilateral 
      paralysis was observed in 77.03% (n = 57). These were common complaints of 
      Lagophthalmos, otalgia, facial drooping, dysarthria, and compromised forehead 
      wrinkling. The treatment regimen mainly included the use of corticosteroids 
      (n = 51) (69.86%), antivirals (n = 23) (31.51%), IVIG (n = 18) (24.66%), 
      antibiotics (n = 13) (17.81%), antiretroviral (n = 9) (12.33%), and antimalarial 
      (n = 8) (10.96%) medications. In all, 35.62% of patients (n = 26) adhered to a 
      combination of antiviral and corticosteroid-based therapy. Positive treatment 
      outcomes were observed in 83.58% (n = 56) of cases. In contrast, 10 patients 
      (14.93%) showed nonsignificant recovery, out of which 3 (4.48%) died from the 
      disease. CONCLUSION: The association of facial palsy with COVID-19 is 
      controversial and therefore requires further investigation and published work to 
      confirm a causal relationship. However, physicians should not overlook the 
      likelihood of facial palsy post-COVID-19 infection and treat it accordingly.
CI  - (c) 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
FAU - Khurshid, Aiman
AU  - Khurshid A
AD  - Department of Forensic Medicine Abbasi Shaheed Hospital Karachi Pakistan.
FAU - Khurshid, Maman
AU  - Khurshid M
AD  - Department of Internal Medicine Dow University of Health Sciences Karachi 
      Pakistan.
FAU - Sohail, Aruba
AU  - Sohail A
AD  - Department of Internal Medicine Dow University of Health Sciences Karachi 
      Pakistan.
FAU - Raza, Imran Mansoor
AU  - Raza IM
AD  - Department of Internal Medicine Dow University of Health Sciences Karachi 
      Pakistan.
FAU - Ahsan, Muhammad Khubab
AU  - Ahsan MK
AD  - Department of Internal Medicine Jinnah Medical and Dental College Karachi 
      Pakistan.
FAU - Alam Shah, Mir Umer Farooq
AU  - Alam Shah MUF
AD  - Department of Psychiatric Medicine Dr Ruth KM Pfau Civil Hospital Karachi 
      Pakistan.
FAU - Taseer, Anab Rehan
AU  - Taseer AR
AUID- ORCID: 0000-0002-9168-7041
AD  - Department of Pulmonology, Lady Reading Hospital (LRH) Peshawar Pakistan.
FAU - Nashwan, Abdulqadir J
AU  - Nashwan AJ
AUID- ORCID: 0000-0003-4845-4119
AD  - Hamad Medical Corporation Doha Qatar.
FAU - Ullah, Irfan
AU  - Ullah I
AUID- ORCID: 0000-0003-1100-101X
AD  - Kabir Medical College Gandhara University Peshawar Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20221028
PL  - United States
TA  - Health Sci Rep
JT  - Health science reports
JID - 101728855
PMC - PMC9616168
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - facial palsy
OT  - neurological symptoms
OT  - systematic review
COIS- Abdulqadir J. Nashwan is an Editorial Board member of Health Science Reports and 
      co-author of this article. He is excluded from editorial decision-making related 
      to the acceptance of this article for publication in the journal. The remaining 
      authors declare no conflict of interest.
EDAT- 2022/11/03 06:00
MHDA- 2022/11/03 06:01
PMCR- 2022/10/28
CRDT- 2022/11/02 02:14
PHST- 2022/07/31 00:00 [received]
PHST- 2022/09/13 00:00 [revised]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/11/02 02:14 [entrez]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/11/03 06:01 [medline]
PHST- 2022/10/28 00:00 [pmc-release]
AID - HSR2887 [pii]
AID - 10.1002/hsr2.887 [doi]
PST - epublish
SO  - Health Sci Rep. 2022 Oct 28;5(6):e887. doi: 10.1002/hsr2.887. eCollection 2022 
      Nov.